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LIST OF ABBREVIATIONS 
APC Adenomatous polyposis coli 
CK cytokeratin 
CRD cysteine-rich domain 
CTBP C-terminal binding protein 
CREBBP CREB (cAMP response element-binding)-binding protein, also known as 
CBP  
CTNNB1 β-catenin 
CTNNBIP1 beta-catenin, interacting protein 1 
dsh dishevelled (in Drosophila) 
DVL dishevelled (in human) 
EMA epithelial membrane antigen 
ES Ewing sarcoma 
EWS Ewing sarcoma gene/protein 
FISH fluorescent in-situ hybridisation 
FLI1 Friend leukaemia virus integration 1 
FZD Frizzled  
GSK3β glycogen synthase kinase 3 beta 
HMWCK high molecular weight cytokeratin 
IGFBP3 insulin growth factor binding protein 3 
LEF lymphoid enhancer-binding factor 
LRP low-density lipoprotein receptor-related protein 
MMTV mouse mammary tumour virus 
NSE neuron-specific enolase 
PCP planar cell polarity 















PNET peripheral neuroectodermal tumour 
RB retinoblastoma 
RT-PCR reverse transcriptase polymerase chain reaction 
sFRP secreted frizzled-related protein 
TCF T cell factor 
TDT terminal deoxynucleotidyltransferase 
TGF transforming growth factor 
TLE1 transducin-like enhancer of split 1  
VEGF vascular endothelial growth factor 
WIF WNT inhibitory factor 
WLS wntless  















PART A: PROTOCOL 
1.  PROJECT TITLE  
The WNT signalling pathway in Ewing sarcoma/primitive neuroectodermal tumour: an 
immunohistochemical investigation 
2.  SHORT DESCRIPTION OF THE PROJECT 
The WNT pathway is a major developmental pathway that plays an important role in the 
development of many tumours, including neuroectodermal and bone tumours.  Ewing 
sarcoma (ES) / primitive neuroectodermal tumour (PNET) shows varying degrees of 
neuroectodermal differentiation and is the second commonest bone malignancy in 
childhood.  A recent study on ES cell lines using RT-PCR analysis and biological response 
assays suggests that an intact WNT pathway exists in ES and that addition of exogenous 
WNT ligands enhances cell motility.  Based on this we hypothesize that the WNT pathway 
may play a role in the biology of ES/PNET and we aim to investigate this by 
immunohistochemical stains on archival tissue. 
3.  COLLABORATORS 
Nil 
4.  PROJECT 
4.1.  AIM 
To identify alterations in the WNT signalling pathway in ES/PNET and to determine if this 
holds any role in the pathobiology of ES/PNET. 
4.2.  OBJECTIVES 
To perform immunohistochemical staining of ES/PNET cases using antibodies against 
multiple components of the WNT pathway: WNT1, WNT5A, dishevelled, phosporylated 
GSK3β (glycogen synthase kinase 3 beta), β-catenin, MYC, cyclin D1, E-cadherin 
















To correlate expression patterns of the immunohistochemical stains with clinical data and 
histological features: 
1. To discuss the possible reasons for the patterns of immunohistochemical expression in 
ES/PNET 
2. To elucidate the role of WNT pathway in ES/PNET 
4.3.  BACKGROUND 
ES/PNET are primary malignant small round cell tumours of bone and soft tissues.  They 
are the second most common malignant bone tumours of childhood (osteosarcoma being 
the commonest) and account for 6% of all malignant bone tumours.  Traditionally ES and 
PNET have been differentiated from each other based on the absence and presence of 
neuroectodermal differentiation respectively.  However, immunohistochemical and 
molecular studies indicate that they are the same entity, so they are currently often referred 
to as ES/PNET.  ES/PNET are characterised by chromosomal translocations involving the 
EWS gene and a member of the ETS family of transcription factors, usually Friend 
Leukaemia virus Integration 1 (FLI1).  They range morphologically from small 
undifferentiated cells to larger, less uniform cells with varying degrees of neuroectodermal 
differentiation.
1
   
The WNT pathway is a highly conserved pathway occurring in many animals, including 
the fruitfly Drosophila (Wingless pathway), mouse (Int pathway) and humans.  It controls 
cell fate, proliferation, migration, tissue architecture and organogenesis during embryonic 
development and is a critical pathway in neuroectodermal development.  In the adult this 
pathway regulates haematopoiesis, osteogenesis, angiogenesis, as well as adipogenesis, 
and its ligands, the WNT proteins, are normally secreted in bones, muscle and soft tissues.
2
   
Abnormalities of this pathway are present in many cancers, for example: APC gene 
mutation is one of the first mutations to occur in the development of colon cancer;
3
 
abnormal WNT5A expression is an indicator of poor prognosis in neuroblastomas 
(underexpression)
4
 and malignant melanomas (over expression);
5
 nuclear β-catenin 
expression is a significant indicator of favourable prognosis in medulloblastomas
6
 but 

















A RT-PCR study on nine ES cell lines found that most cell lines express certain 
components of the WNT pathway (such as WNT10B, WNT5A, WNT11, WNT13, FZD2, 
FZD3, FZD4, FZD7, FZD8 and LRP5/6) but not other components (WNT1, WNT2, 
WNT3, WNT3A, WNT7A, FZD1, FZD6, FZD9 and FZD10).  It was reported that an 
intact WNT pathway was present in these cell lines, and that exogenous stimulation by 
WNT3A ligand caused markedly increased cytoplasmic β-catenin expression, 3-5 fold 
increase in cell chemotaxis, but no increase in cell proliferation.  Immunohistochemical 
staining for β-catenin was then done on seven cases but all cases were negative.
8
  Although 
this investigation on ES cell lines suggested a potential pathway for metastasis, it was not 
correlated with clinicopathological parameters and was limited by the small number of 
cases.   
Neuroblastomas, malignant melanomas, medulloblastomas and ES/PNET all belong to the 
group of neuroectodermal tumours.  The findings in these tumours raise the possibility that 
the WNT pathway may play a role in the biology of ES/PNET.  However, there is a 
relative lack of immunohistochemical testing and clinicopathological correlation in 
ES/PNET.  We would therefore like to investigate the expression of WNT pathway 
proteins in ES/PNET by immunohistochemistry and to correlate the results with available 
clinicopathological parameters. This may lead to a better understanding of the 
pathobiology of ES/PNET and potentially aid in its management. 
4.4.  REFERENCES 
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cancer. J. Clin. Pathol. 2003; 56; 69-73. 
10. Chetty R, Serra S, Salahshor S et al. Expression of Wnt-signaling pathway proteins in 
intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray 
analysis. Hum. Pathol. 2006; 37; 212-217. 
 
4.5.  DETAILED METHODOLOGY 
4.5.1.  Cases 
1. This is a retrospective study. 
2. The databases of the Division of Anatomical Pathology, University of Cape Town, 
Groote Schuur Hospital, Red Cross War Memorial Children’s Hospital, and 
Anatomical Pathology Laboratory Greenpoint, Cape Town will be searched for all 
cases of ES/PNET. 
3. Cases will be allocated study numbers and patients’ names and other identification 
details will be not be used. 
4. All stained slides of the cases will be retrieved and reviewed. 
5. The diagnosis in each case will be confirmed and the morphological data (including 
results of special stains) recorded. 
6. Blocks from the confirmed cases will be retrieved and additional sections cut for 
immunohistochemistry. 
4.5.2.  Antibodies 
The following primary antibodies will be used (Table 1): WNT1, WNT5A, DVL1, 
phosporylated GSK 3β, β-catenin, MYC (also known as c-myc), cyclin D1, E-cadherin 















Table 1: Primary antibodies. 
Primary antibody Clone Supplier 
WNT1 ab15251 (polyclonal) Abcam 
WNT5A ab72583 (polyclonal) Abcam 
DVL1 ab21062 (polyclonal) Abcam 
GSK3β  ab30619 (polyclonal) Abcam 
β-catenin 17C2 (monoclonal) Novo-castra 
MYC 9E11 (monoclonal) Novo-castra 
Cyclin D1 SP4 (monoclonal) Lab Vision 
E-cadherin (extracellular domain) 36B5 (monoclonal) Novo-castra 
E-cadherin (cytoplasmic domain) 36/E-cadherin (monoclonal) BD Biosciences 
 
4.5.3.  Staining procedure 
Paraffin wax embedded tissue sections will be stained using standard techniques.  
1. Paraffin wax embedded sections will be cut onto 3-aminopropyltriethoxysilane 
(APES) coated slides and heat-fixed overnight at 60°C to adhere sections to slides. 
2. Sections will be dewaxed through xylene, rehydrated in graded ethanols, and washed 
in water. 
3. Endogenous peroxidase activity will be blocked by treating slides with a 1% H2O2 in 
water solution for 15 minutes. 
4. Slides will be washed well in water. 
5. Antigen retrieval will be performed by pressure-cooking slides in either citrate buffer 
at pH 6 for 2 minutes or EDTA (pH8) for 1 minute at full pressure. 
6. Slides will be immediately immersed in water. 
7. Slides will be rinsed with phosphate buffered saline solution (PBS pH 7.6). 
8. Non-specific binding will be blocked by treating slides with a 5% Goat Serum 
Solution (DAKO #X0907). 















10. Sections will be incubated with primary antibody at room temperature at specified 
times and dilutions. 
11. Sections will be washed well with PBS Buffer. 
12. Sections will be incubated with DAKO Envision labelled Polymer, HRP (DAKO 
#K4001) for 30 minutes at room temperature. 
13. Sections will be washed well with PBS buffer. 
14. Positivity will be developed by applying 3.3 – diaminobenzidine (DAKO K3466) for 
5-10 minutes. 
15. Slides will be washed in water. 
16. Slides will be immersed in a 1% CuSO4 solution for 5 minutes. 
17. Slides will be washed in water. 
18. Slides will be counterstained in haematoxylin, blued in Scott’s tap water. 
19. Slides will be washed in water, dehydrated using graded alcohols, cleared with xylene 
and mounted with rapid mountant medium. 
 
4.5.4.  Grading of staining 
β-catenin immunostaining will be scored according to the protocol used by Jass et al.
9
   
This protocol scores 1 for loss of cell membrane staining, 1 or 2 for slight and pronounced 
increase in cytoplasmic staining, respectively, and 1 or 2 for slight and pronounced nuclear 
staining, respectively, giving a maximum score of 5.  Cases scoring 4 or more will be 
regarded as positive for abnormal β-catenin immunolocalisation.  
For the other antibodies the immunostaining score will be based on the protocol used by 
Chetty et al.
10
  The scoring will be as follows: moderate and/or strong immunolabelling 
will be regarded as positive, with quantification of the positivity as follows: a score of 0 (or 
negative), less than 5% tumour cells stained; a score of 1 (or focal positivity), 6% to 50%; 
and a score of 2 (or diffuse positivity), more than 50%.  In addition, the cellular location of 
















4.6.  CLINICAL CORRELATION 
Results of immunostaining of each antibody will be correlated with available clinical data, 
tumour morphology, and with immunostaining of other antibodies.  The clinical and 
morphological features to be compared include: age (≤ 12 / >12 years of age), gender 
(male / female), site (skeletal / extraskeletal), location (central / peripheral), metastasis 
(present / absent), mitotic count (≤ 10 / > 10 mitoses per 10 high power fields), nucleoli 
(inconspicuous / prominent) and neuroectodermal differentiation (present / absent).   
4.7.  STATISTICAL ANALYSIS 
For each clinical and morphological feature, immunostaining median scores will be 
divided into two subgroups and compared using the two-sample Wilcoxon rank-sum 
(Mann-Whitney) test since these data were not normally distributed.  For analysing the 
relationship between scores of the antibodies (comparing more than two medians, the 
median immunostaining score of a given antibody by scores of another antibody), the 
Kruskall-Wallace equality of rank test (with ties) will be employed.  A p-value of less than 
0.05 will be used as the standard cut-off for statistical significance.  All analyses will be 






















PART B: LITERATURE REVIEW 
1. OBJECTIVES OF LITERATURE REVIEW 
 To review the current literature on Ewing sarcoma (ES)/Primitive neuroectodermal 
tumour (PNET). 
 To review the current literature on the WNT signalling pathway. 
 To review the current literature on the WNT signalling pathway in ES/PNET. 
 To identify gaps or needs for future research. 
2.   LITERATURE SEARCH STRATEGY 
2.1.  STUDY SEARCH 
Journal articles were searched for using various internet search engines, including: 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), Google Scholar 
(http://scholar.google.co.za) and Scirus (http://www.scirus.com).  The search terms used 
included: Ewing sarcoma, PNET, WNT and names of individual WNT pathway 
components such as WNT, E-cadherin, cyclin D1 and MYC (also known as c-myc).  
Names of individual genes were verified using the “Entrez Gene” database 
(http://www.ncbi.nlm.nih.gov/gene) and the “Human Gene Nomenclature” database 
(http://www.genenames.org/cgi-bin/hgnc_search.pl). 
Other resources used to retrieve further journal references included standard surgical and 
specialized pathology textbooks and “The Wnt Homepage” by Roel Nusse 
(http://www.stanford.edu/~rnusse/wntwindow.html).   
The full text of the journal articles were retrieved electronically from the journal website, 
PubMed, and by using the electronic journal portals (http://www.tdnet.com/rlc/and 
http://uctsfx.hosted.exlibrisgroup.com/) of the library of the University of Cape Town 
(UCT).  When the articles were not available electronically, they were retrieved physically 
from the UCT Faculty of Health Sciences library, and if not available from the UCT 















Selected article titles and their abstracts were reviewed to identify articles relevant to the 
topics discussed.  No attempt was made to provide an exhaustive review of either 
ES/PNET or the WNT pathway in general. 
2.2.  INCLUSION CRITERIA 
1. Review articles on ES/PNET. 
2. Review articles on the WNT pathway. 
3. Original research articles investigating the WNT pathway in human diseases. 
4. Original research articles investigating the WNT pathway in human neoplasms, 
particularly ES/PNET. 
2.3.  EXCLUSION CRITERIA 
Non-English language literature was excluded. 
2.4.  QUALITY CRITERIA 
1. The more recent review articles were preferred over the older review articles. 
2. The original articles describing the first discovery of an entity were preferred.   
3. Studies with large numbers of cases were preferred. 
4. Articles in journals with a high impact factor were preferred (impact factor is looked up 
via http://admin-apps.isiknowledge.com/JCR/JCR).   
5. For WNT pathway, articles by eminent authors with multiple publications in the field 
of WNT research were preferred. 
6. For ES/PNET, articles by eminent authors and those that were referenced in surgical 
pathology textbooks and in the WHO manual (Pathology and Genetics of Tumours of 















3.  LITERATURE REVIEW 
3.1.  EWING SARCOMA / PNET 
Ewing sarcomas (ES) / primitive neuroectodermal tumours (PNET) are round cell 
sarcomas with consistent EWS gene re-arrangements
1
 and varying but usually minimal 
degrees of neuroectodermal differentiation.
2
  Despite the presence of neuroectodermal 
differentiation, current evidence favours the cell of origin in ES/PNET to be CD133+ bone 
marrow-derived mesenchymal stem cell.
3, 4
 
ES/PNET includes ES, PNET and Askin tumours.  While immunohistochemical and 
cytogenetic studies indicate that these tumours are the same entity, Ewing sarcoma and 
PNET have traditionally been distinguished from each other based on the absence or 
presence of neuroectodermal differentiation on light microscopic, immunohistochemical, 
or ultrastructural studies respectively.
5
 
3.1.1.  History 
PNET was first described in 1918 by Arthur Purdy Stout in a case report of a 42 year old 
man with an ulnar nerve tumour composed of undifferentiated round cells that formed 
rosettes 
6
.  ES was first described in 1921 by James Ewing in a case report of a 14-year old 
girl with a round cell neoplasm in the radius; in that report he proposed the term “diffuse 
endothelioma of bone”.
7
  Askin tumour was first described in 1979 by Frederic Askin in a 




3.1.2.  Epidemiology 
In the United States, the overall incidence of ES/PNET appears to be stable and is 2.93 per 
million people for the period 1973-2004.
9
  In the general population, ES/PNET accounts 
for 6-8% of primary bone malignancies.
5
  In children, it is the second commonest primary 
bone malignancy after osteosarcoma.  In people older than 20 years it is the fourth 
commonest primary bone malignancy, after myeloma, osteosarcoma and chondrosarcoma.  
ES/PNET most commonly occurs between the ages of 5 and 20 years, the peak incidence 
being the second decade and median age being 14 years (Figure 1).  ES/PNET is rare 
before the age of 5 years and over the age of 40 years.
10
  Below the age of 5 years, 

















































Figure 1: Incidence of bone sarcomas by type from the Surveillance Epidemiology and 
End Results (SEER) data (1975-2000) (modified from Mascarenhas et al., 2006).
12
 
The male : female ratio is 1.4:1.  In the United States, ES/PNET is commonest in Whites 




3.1.3.  Sites of involvement 
Approximately 76% of cases of ES/PNET are skeletal in origin.
14
  Skeletal ES/PNET has a 
predilection for the diaphysis and metadiaphyseal regions of long bones.  Involvement of 
the pelvis is also common.  Ribs, scapula and vertebra (thoracic, lumbar and coccygeal) are 


















Table 1: Skeletal distribution of ES/PNET compared to chondrosarcoma and osteosarcoma 
from SEER data (1992-2002) (modified from Mascarenhas et al., 2006).
12
 
 ES/PNET Chondrosarcoma Osteosarcoma 
Lower limb long bones 22% 22% 68% 
Pelvis 28% 23%  5% 
Clavicle, rib, sternum 14%  9%  3% 
Vertebra 12%  6%  1% 
Upper limb long bones & scapula 11% 14% 10% 
Feet  4%  1%  1% 
Skull  3% 15%  9% 
Hand  1%  1% <1% 
 
Extraskeletal ES/PNET commonly involves the deep soft tissues of extremities, such as the 
upper thigh and buttock, followed by the upper arm and shoulder.  Less commonly they 
may be paravertebral or close to the ribs.  They may be attached to a major nerve.  
Although rare, virtually any organ site can be involved.
16
  In a study of 130 extraskeletal 
ES/PNET, the commonest primary sites were: trunk (32%), extremity (26%), head and 
neck (18%), and retroperitoneum (16%).
17
 
3.1.4.  Clinical features  
The commonest symptoms are localised pain and swelling, usually less than a year in 
duration.  Common signs include fever, leukocytosis and anaemia.  There may be local 
erythema and the clinical differential diagnosis often includes osteomyelitis.  Even at 
surgery, the tumour may have a yellow semi-liquid appearance resembling pus.  Patients 
may also present with complications such as pathological fracture and metastatic disease.  
Metastases are present in 25% of the patients at the time of presentation; with 38% to the 
lungs, 31% to other bones particularly the skull, and 11% to the marrow.  Other sites 
include the central nervous system and rarely regional lymph nodes.
5, 9, 16
 
3.1.5.  Imaging 
Classically imaging shows a poorly defined permeative (“moth-eaten” or “rotten-wood”) 















(Figure 2).  Expansile bone destruction with soap-bubble appearance and sclerotic lesions 
with bone expansion has also been described.   
 
Figure 2: X-ray of a case of Ewing sarcoma involving the tibia showing extensive soft 
tissue involvement with subtle extension into the cortex of the diaphysis and minimal 
periosteal reaction. 
Computed tomography is useful to demonstrate the extent of bone destruction.  Magnetic 















hypointense on T1-weighted images (compared to marrow), and hyperintense on T2 
(compared to muscle).  On bone scan, ES shows increased uptake.
5, 16, 18
 
3.1.6.  Macroscopy 
ES/PNET are poorly demarcated, tan-grey, soft, often necrotic and haemorrhagic tumours 




Figure 3: Forearm of a 17 year old white female (amputated in 1938) showing on bisection 
a metadiaphyseal tumour in the proximal ulnar (extent demarcated by arrows) with 
permeative growth through the bone to involve the soft tissues (arrow head).  Tumour cut 
surface was tan with areas of haemorrhage.   
3.1.7.  Histopathology 
ES/PNET is the prototypical small round blue cell tumour of childhood, characteristically 














nuclei, scanty cytoplasm, and no matrix production.  Nucleoli are usually inconspicuous.  
Cytoplasm is clear to eosinophilic and may contain glycogen.  Cell borders are poorly 
defined.  Necrosis is common and the tumour may show a peritheliomatous growth pattern 
with viable cells surrounding blood vessels.  A light-and-dark pattern of viable (light) and 
apoptotic (dark) tumour cells may also be seen.   
Homer-Wright rosettes may be seen and indicates a diagnosis of PNET traditionally.  
Atypical ES or large cell ES refers to the presence of large pleomorphic nuclei and 
prominent nucleoli (Table 2).
19, 20
Cytoplasm also tends to be more abundant and the
reticulin framework more prominent in atypical ES.
21
Atypical ES has also been used to 
describe ES with non-conventional morphology, such as ES with spindle-cell sarcoma-like
(synovial sarcoma-like), sclerosing, clear cell (hypernephroid), or vascular-like with 
haemangioendothelioma-like features.
19, 22
An adamantinoma-like variant of ES with nests 
of epithelioid cells that are positive for high molecular weight cytokeratin has been 
described in 5% of cases.
19, 23
Isolated cases of ES/alveolar rhabdomyosarcoma 
(ectomesenchymoma),
24






Table 2: Light microscopic features in ES/PNET (modified from Folpe et al., 2005; 
Navarro et al., 1994).
19, 27
Feature Classical ES Atypical ES PNET 
Cell shape Uniform, round Pleomorphic, spindled Irregular 
Cell size Small Large Medium 
Chromatin Fine Coarse Coarse 
Cytoplasm Scanty Abundant Moderate 
Glycogen Abundant Moderate Scanty 
Nucleoli Inconspicuous Prominent Prominent 
Rosettes Absent Absent Present 
3.1.8.  Immunophenotype 
ES/PNET typically show immunoreactivity for vimentin, CD99 (O13, HBA-71, mic-2), 















enolase (NSE), CD57, synaptophysin, cytokeratin and CD117.
19
  Caveolin 1 (CAV1) is a 
novel marker reported to be present in 96% of cases of ES/PNET and may be a potential 
diagnostic marker.
22
   
CD99 is a sensitive marker present in 88-100% of ES/PNET cases and can also be used on 
fine needle aspirate specimens.
19, 22, 28, 29
  However, CD99 is also seen in other tumours, 
some of which may display a small round blue cell morphology, including: mesenchymal 
chondrosarcoma (100%), lymphoblastic lymphoma (93%), granulosa cell tumour (88%), 
synovial sarcoma (70%), malignant melanoma (60%), granulocytic sarcoma (55%), Merkel 
cell carcinoma (55%), rhabdomyosarcoma (up to 40%), desmoplastic small round cell 
tumour (35%), osteosarcoma (32%) and small cell carcinoma (6%).
30-40
 
FLI1 staining is nuclear and is a more specific but less sensitive (74-91%) marker for 
ES/PNET than CD99.  FLI1 expression is limited to ES/PNET with EWS-FLI1 
translocations.  FLI1 is expressed in normal endothelial cells and lymphocytes.  It is often 
expressed in vascular tumours, desmoplastic small round cell tumours, olfactory 




An antibody to EWS has been developed and staining is seen in approximately 90% of 




NSE expression is on-specific, but may indicate neuroectodermal differentiation.  
Neuroectodermal differentiation carries no prognostic significance.
20
 
KIT (also known as c-kit or CD117) expression occurs in approximately 20-40% of 
ES/PNET, but its therapeutic and prognostic significance is uncertain as mutations in the 
KIT gene are rare in ES/PNET.
19, 43
 
Pancytokeratin (such as AE1/AE3) may be positive in 30% of cases.  The adamantinoma-
like variant of ES/PNET typically expresses high molecular weight cytokeratins 

















Expression of p53 is seen in approximately 10% of ES/PNET and appears to be associated 
with an extremely poor outcome.
44
  Loss of immunoexpression of cyclin-dependent kinase 
inhibitor 2A (CDKN2A, also known as p16 or p16INK4a) has been associated with 
metastatic disease at presentation.
45
 
3.1.9.  Ultrastructure 
Electron microscopy reveals primitive cells containing intracytoplasmic glycogen granules 
and few organelles. Neuroectodermal differentiation is characterised by fine cytoplasmic 
processes (neuritic or dendritic processes), primitive intercellular junctions, neurosecretory 
granules (50-150nm), and microtubules (neurotubules) (Table 3).
21, 27, 28
 
Table 3: Ultrastructural features in ES/PNET (modified from Llombart-Bosch et al., 1978; 
Navarro et al., 1994).
21, 27
 
Feature Classical Ewing sarcoma Atypical Ewing sarcoma PNET 
Glycogen Abundant Moderate Rare 
Organelles Scarce Moderate Abundant 
Dense-core granules Absent Rare Abundant 
Neurotubules Absent Rare Abundant 
Neuritic processes Absent Rare Abundant 
 
3.1.10.  Genetics 
Virtually all ES/PNET are characterised by the translocation of EWS gene (22q12) to one 
of the ETS family members.  The resulting fusion protein is formed by the N-terminal 
transcriptional activation domain of EWS fused to the C-terminal DNA binding domain of 
the ETS partner.  The ETS partner is FLI1 (11q24) in 85% of cases and ERG (21q22) in 10-
15% of cases.  In the remainder it is either ETV1 (7p22), E1AF (17q12), FEV (2q33), or 
PATZ1 (ZSG, 21q12.2).
1, 46, 47
  Interestingly, isolated cases resembling ES/PNET 
morphologically and immunophenotypically and characterised by functionally similar 
fusion proteins not involving EWS (e.g. FUS-FEV), not involving ETS (e.g. EWS-SP3), or 
















Molecular diagnostic methods can be used to confirm a diagnosis of ES/PNET, especially 
in atypical cases.
19
  The molecular methods include fluorescent in-situ hybridisation
(FISH), chromosome banding, reverse transcriptase polymerase chain reaction (RT-PCR), 
and Southern blotting.  RT-PCR can be used to detect minimal residual disease by 
detecting fusion transcripts in the peripheral blood or marrow.
5
  In formalin-fixed paraffin-
embedded tissues, RT-PCR has a sensitivity of 54% and a specificity of 85%, whereas 
FISH has a sensitivity of 91% and a specificity of 100%, using either fusion probes (EWS 
and FLI1) or the commercial EWS break-apart probes.
52
The EWS break-apart probes use two probes that flank the EWS break-point to detect 
t(22q12) translocations.  However, it is not specific for ES/PNET, as EWS translocations 
may also occur in other tumours (Figure 4).
53, 54
Figure 4: Tumours which may show EWS translocations (modified from Shing & 
Coleman, 2003).
54
The EWS-ETS chimeric proteins function as transcription factors that bind to ETS targets, 
and based on integrative analysis of gene expression profiling experiments more than 200 
genes have been found to be up-regulated by the EWS-FLI1 fusion product.
55














upregulated genes involve cell cycle and proliferation control such as cyclin D1 promoter, 
cyclin E promoter, NR0B1 (DAX1) and VEGF promoter.
56-59
  Other upregulated genes
include genes involved in intracellular signalling (protein kinase C β, caveolin 1), neuronal 
development (NKX2-2), and neural crest development (MYC, cholecystokinin and 
microtubule associated protein tau).
55, 60-62
EWS-ETS fusion proteins also repress many genes, including cyclin-dependent kinase 
inhibitor 1A (CDKN1A, also known as p21) promoter, TP53, GADD45A, GADD45B, 
TGFβ type II receptor promoter, IGFBP3 promoter, FOSL and TCF7L.
55, 63-66
The commonest secondary genetic mutation is inactivation of p16.
67
This allows stable
expression of EWS-FLI1 by preventing EWS-FLI1 induced apoptosis and is also 
associated with a poor outcome.
67, 68
Other abnormalities include increased expression of
MYC, MYB, SRC and RAF1.
69
Mutations in TP53 and RB are rare.
70
Chromosome copy
number changes are frequent (particularly gains at 1q, 2, 8 and 12 and losses at 9p and 
16q), with higher copy number changes associated with worse prognosis.
71
3.1.11.  Prognostic factors
Historically, overall survival is poor (41%) but with modern therapy prognosis has 
improved for non-metastatic disease, which occurs in approximately 75% of patients.  In 
this group, the overall survival is approximately 70%, whereas the overall survival for
metastatic disease is approximately 20 to 30%.
72, 73
High stage, recurre t disease, size of tumour >8cm, central location, older age (age ≥18 
years worse than age 10-17 years worse than age <10 years) and elevated lactate
dehydrogenase (LDH) levels at presentation are statistically significant indicators of worse
prognosis.
72, 74, 75
Non-Hispanic Caucasians are reported to have the best outcome, and 
African Americans the worst.
14
Histologically, lobular growth pattern, atypical ES/PNET
morphology and higher mitotic activity (5 or more mitoses per 10 high power fields) 
correlate with worse survival but none are independently prognostic on multivariate 
analysis.
22, 28
Molecular indicators of poor prognosis include TP53 mutations, p16 alterations and 















D1, or NKX2-2 transcription factor.
44, 75, 76
  With regards to EWS-ETS fusion status, 
although 2 earlier retrospective studies reported that patients with type-1 fusion (EWS exon 
7 fused to FLI1 exon 6) perform better than those with larger, less common fusion 
transcripts.
77, 78




3.1.12.  Differential diagnosis 
The differential diagnosis includes other small round cell malignant neoplasms (Table 4).   
Table 4: Immunohistochemical profile of ES/PNET and its mimics (modified from 
Hameed, 2007; Rossi et al., 2004).
81, 82
 
Tumour   CD99 FLI1 LCA TDT CK Chr S100 NB84 
ES/PNET + + - - +/- - +/- +/- 
DSRCT + +/- - - + +/- +/- +/- 
LBL/ALL + + +/- + +/- - - - 
Other lymphomas +/- + + - - - - - 
Mesenchymal CS + - - - - - + - 
Neuroblastoma - - - - - + +/- + 
Rhabdomyosarcoma +/- - - - - - +/- +/- 
Synovial sarcoma +/- - - - +/- - +/- ND 
Small cell OS +/- ND - - +/- - +/- +/- 
Melanoma +/- + - - - - + - 
Small cell carcinoma - ND - - + + - - 
Merkel cell carcinoma +/- + - - + + - ND 
LCA, leukocyte common antigen; TDT, terminal deoxynucleotidyltransferase; CK, pan-
cytokeratin; Chr, chromogranin; DSRCT, desmoplastic small round cell tumour; 
LBL/ALL, lymphoblastic lymphoma/acute lymphoblastic leukaemia; CS, chondrosarcoma; 
OS, osteosarcoma; ND: no data; + positive; - negative; +/- variable positivity. 
Both neuroblastomas and ES/PNET are small round cell malignant neoplasms which may 
contain Homer-Wright rosettes.  Neuroblastomas and approximately 20% of ES/PNET 
also express NB84.
83
  However, neuroblastomas occur in a younger age group, often have 
elevated urinary catecholamine metabolite levels, may show ganglionic differentiation, and 















also rarely contain glycogen, and are CD99 and t(11;22) negative.
83
  Dystrophic 
calcification in necrotic areas, common in neuroblastomas, is rare in ES/PNET.
16
 
Alveolar rhabdomyosarcoma often shows an alveolar growth pattern with central 
discohesion.  Multinucleated giant cells with marginally placed nuclei and eosinophilic 
rhabdomyoblasts with or without cross striations may also be present.  Solid forms of 
alveolar rhabdomyosarcomas can resemble ES/PNET.  Depending on the study reported, 
different rates of CD99 positivity has been reported, ranging from 0 to 40% of 
rhabdomyosarcomas, and seems to be more common in the embryonal subtype.
30, 84-86
  
Desmin may rarely be expressed in ES/PNET.
19
  Myogenin and MyoD1 are specific 
markers for rhabdomyosarcomas.  Approximately 80% of cases of alveolar 
rhabdomyosarcoma also harbour specific translocations between the forkhead box O1 gene 
(FOXO1) on chromosome 13 and the paired box (PAX) family of genes.  The specific 
translocations are: t(2;13)(q35;q14) PAX3-FOXO1 translocation in 60% of cases, and 
t(1;13)(p36;q14) PAX7-FOXO1 translocation in 20% of cases.
87
  The remaining cases are 
fusion negative and are often seen in the solid form of alveolar rhabdomyosarcomas.
88
 
Non-Hodgkin’s lymphoma, particularly lymphoblastic lymphoma can mimic ES/PNET, 
CD99 being positive in most T cell lymphoblastic lymphomas, and CD45 being negative in 
a proportion of lymphoblastic lymphomas.
89
  However, TDT is positive in lymphoblastic 
lymphomas, and lymph node enlargement is rare in ES/PNET. 
Small cell carcinoma and other neuroendocrine carcinomas such as Merkel cell carcinoma 
tend to occur in the older age group (age >45 years).  ES/PNET can express cytokeratin 
and neuroendocrine markers,
19
 but CD99 is only positive in 6% of cases of small cell 
carcinomas.
34
  Merkel cell carcinoma can show immunoexpression of CD99 and FLI1 in 
up to 55% and 90% of cases respectively.
90
  However, dot-like CK20 positivity and 
vimentin negativity aids in differentiating Merkel cell carcinoma from ES/PNET.
31
 
Mesenchymal chondrosarcoma occurs in young adults and like ES/PNET is CD99 positive.  
The diagnosis depends on the presence of well differentiated cartilage intimately admixed 
with undifferentiated round cells, in a vascular background with haemangiopericytic 
vessels.  The cartilage may be absent in small biopsies.  They are NSE and S100 positive 

















Small cell osteosarcoma occurs in young adults.  Diagnosis requires the presence of small 
malignant cells forming osteoid.  Isolated cases with osteosarcomatous phenotype (osteoid 
production) and ES/PNET genotype (EWS-FLI1 translocations) have been reported.
26
 
Poorly differentiated synovial sarcomas occur in adults and may have a small round cell 
appearance.  CD99 is often positive but cytokeratin, uncommon in ES/PNET, is expressed 
in around 50%.  Diagnosis may require the demonstration of the t(X;18) SSX1-SYT or 
SSX2-SYT fusion transcript characteristic of synovial sarcomas. 
Desmoplastic small round cell tumour (DSRCT) occurs in young adults.  CD99 is seen in 
up to 35% of cases but DSRCT is  characteristically associated with abundant desmoplastic 
stroma and shows polyphenotypic immunoexpression of cytokeratin, EMA and desmin 
(often with perinuclear dot-like positivity)in more than 95% of cases.
33
  DSRCT also 
immunolabels with WT1 in 90% of cases due to underlying t(11;22)(p13;q12) EWS-WT1 
translocation.
33, 92
  However, up to 20% of ES/PNET (and up to 100% of 
rhabdomyosarcomas) also show WT1 expression.
86
 
Malignant melanoma expresses CD99 in 60% of cases.
32
  Small cell malignant melanoma 
is a rare variant that typically arises in a giant congenital naevus and behaves 
aggressively.
93
  When present, melanin pigment and background naevus aid in the 
diagnosis, which can be confirmed by immunopositivity for melanocytic markers (such as 
















3.2.  WNT PATHWAY 
From the hydra to humans, WNTs form a family of evolutionarily conserved secreted 
protein ligands that bind to neighbouring cell surface receptors to guide the fate of the 
cells, from cell migration and morphogenesis in the embryo to tissue homeostasis and 
regeneration in the adult.  WNT, pronounced “wint”, was coined by Nusse et al as a 
combination of the fruit fly wingless (wg) gene and the mouse Int1 gene.
94
  Wg was 
discovered in the fruit fly Drosophila menalogaster as a recessive mutation causing absent 
wings and haltere.
95
  Int1 was discovered in the mouse as an oncogenic integration site for 
the mouse mammary tumour virus (MMTV), which, as the name indicates, causes 
mammary carcinomas in mice.
96
  Subsequently wg and Int1 were found to be homologs 
based on their encoded amino-acid sequences.
97
  Int1 in the mouse has been renamed Wnt1 
as Int2 and Int3 are unrelated genes.   
3.2.1.  Members 
WNTs are defined according to their amino acid sequences rather than their functions, 
which are complex and pleiotropic.
98
  WNTs are glycolipoproteins containing a signal 
sequence followed by a highly conserved distribution of 21 specifically spaced cysteines.
99
  
They bind to receptors with cysteine-rich domains (CRDs); these receptors include 
Frizzled (FZD), low-density lipoprotein receptor-related protein (LRP), and the 
transmembrane tyrosine kinases RYK and ROR2.   
There are currently 19 WNT genes in humans and mice, 14 in the sea anemone 
Nematosteall vectensis, 7 in Drosophila, and 5 in Caenorhabditis elegans.  This broad 
diversity indicates that WNT genes have evolved since at least 600 million years ago.   
The names of the WNT genes in humans are: WNT1, WNT2, WNT 2B (WNT13), WNT3, 
WNT 3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT 9A 
(WNT14), WNT9B (WNT15), WNT10A, WNT10B (WNT 12), WNT11 and WNT16.  Those 




FZD receptors belong to the family of G-protein coupled receptors (GPCRs).  FZD has an 
extracellular long N-terminal extension (cysteine-rich WNT binding domain), a serpentine 














forms of FZDs are called secreted frizzled-related proteins (sFRPs).  Secreted FRPs 
contain CRDs but no transmembrane segments; they bind to WNT and act as WNT 
inhibitors.  There are currently 10 FZD receptors in humans, numbered from FZD1 to 
FZD10. 
LRPs are members of the low density lipoprotein receptor family.  LRP 5/6 are single-pass 
transmembrane molecules and are required for WNT signalling when WNTs bind to 
FZD.
102, 103
3.2.2.  WNT secretion
In the endoplasmic reticulum, WNTs undergo post-translational modification by
glycosylation at the amino-termini and palmitoylation at the first conserved cysteine and 
on a serine in the middle of the protein.
104
Palmitoylation renders WNTs lipid soluble and 
water insoluble.  Inhibiting palmitoylation inactivates WNTs
105
.  Secretion requires a 
dedicated transport protein, wntless (WLS), which is localised to the Golgi, cell surface
and endosomes.
99, 106
After WNT is transported to the surface by WLS and secreted, the 
retromer complex, a multi-protein complex, recycles WLS back into the Golgi apparatus 
by retrograde transport in endosomes.  If the retromer complex is absent, WLS is 
mistrafficked to the lysosome and degraded.
107
Once extracellular, WNT moves onto adjacent cells and activates target genes in a 
concentration-dependent manner, a mechanism by which it provides positional information 
and regulates morphogenesis.  Short range diffusion is facilitated by glypicans on apical 
cell surfaces, whereas WNTs released on the basal lateral aspects of epithelial sheets 

















Figure 5: WNT secretion.  After glycosylation, WNT is palmitoylated by the porcupine 
acyltransferase (1) and exported from the ER into the Golgi (2).  Wntless transport WNT to 
the cell membrane (3) and is recycled by the retromer complex (4).  Extracellular transport 




3.2.3.  WNT signalling pathways 
WNT signalling involves several pathways.  The canonical pathway involves stabilisation 
of β-catenin, primarily affects cell fate, and includes WNT1, 2, 3, 3A, 7A, 8A and 8B.  The 
non-canonical pathways are β-catenin independent, mainly affect cytoskeletal organisation, 
and include WNT 5A and 11.  However, there is extensive cross-talk between the 
pathways so now the WNTs are thought not to be intrinsically “canonical” or “non-
canonical”, but rather the pathway initiated depends on the receptor to which the WNTs 

















  Nevertheless, the pathways are described separately here, as is 
done in the majority of the literature. 
 
Figure 6: Canonical and non-canonical pathways.  The canonical (β-catenin dependent) 
pathway involves binding to the receptors FZD and LRP, which rescues β-catenin from 
APC complex mediated destruction with subsequent translocalisation of β-catenin into the 
nucleus to bind TCF and activate downstream genes such as MYC and cyclin D1.  The 
non-canonical (β-catenin independent) pathways include calcium, SRC, and JNK 
signalling pathways.   
3.2.4.  WNT-β catenin signalling pathway (canonical pathway) 
In the cell there are two β-catenin pools.  One pool is membrane bound and connects E-
cadherin, a cell adhesion molecule, to the actin cytoskeleton.  The other pool is 
cytoplasmic and is regulated by WNT.  In cells not exposed to WNT, cytoplasmic β-
catenin has a half-life of less than an hour
110
 and undergoes phosphorylation, which 
triggers ubiquitination by F-box-containing E3 ubiquitin ligase β-TrCP and degradation in 
the proteasome.
111















synthase kinase 3β (GSK3β).  These 2 enzymes are complexed to the scaffolding proteins 
axin and adenomatous polyposis coli (APC) that position CK1α and GSK3β for 




When WNT binds to FZD and the co-receptor LRP5/6, it brings FZD and LRP into 
proximity, forming a trimer.  The cytosolic domain of FZD then binds dishevelled (dsh in 
the fruitfly; DVL in humans).  FZD, DVL and axin together then allow CK1α and GSK3β 
to phosphorylate the cytosolic tail of LRP.  Phosphorylated LRP binds axin and inactivates 
the axin-APC-CK1α-GSK3β complex.  As a result, nonphosphorylated β-catenin 
accumulates in the cytoplasm and translocates across the nuclear pores into the 
nucleoplasm, where it acts as a transcriptional co-regulator by binding to specific DNA-
binding transcription factors (Figure 6).
98, 109
  Because the WNT/β-catenin pathway relies 
on the stabilisation of β-catenin and protein synthesis, it acts over the course of hours and 
the context it acts in is often cell fate determination and tissue homeostasis.
99
 
The commonest DNA-binding transcription factors that β-catenin binds are the members of 
the T cell-specific transcription factor/lymphoid enhancer-binding factor 1 (TCF/LEF) 
family.  Other nuclear proteins that β-catenin can bind include forkhead box O (FOXO),
113
 
paired-like homeodomain 2 (PITX2),
114






The TCF/LEF family is a group of transcription factors that include TCF1, TCF3, TCF4, 
and LEF1.  In the nucleus, TCF/LEF is normally bound to members of the transducin-like 
enhancer of split (TLE) family and recruits histone deacetylases (HDAC) to form a 
repression complex that silences WNT target genes.  When sufficient levels of β-catenin 
are present in the nucleus, β-catenin replaces the TLE repressors and binds to TCF to 
activate transcription of WNT target genes.
117, 118
 
Other co-activators that are recruited by β-catenin include:  BCL9 (legless in Drosophila), 
pygopus (PYGO), CREB-binding protein (CREBBP), hyrax/parafibromin and SMARCA4 
(also known as BRG1).  BCL9 and PYGO bind to the amino-terminal half of β-catenin; 

















To prevent inappropriate activation of WNT targets by low levels of β-catenin, several 
proteins act as intranuclear “buffers”.β-catenin interacting protein 1 (CTNNBIP1, also 
known as ICAT), chibby, SOX9 and CTBP (C-terminal binding protein) bind to and 
inhibit β-catenin, whereas TLE binds to and inactivates TCF.
99
 
Extracellular inhibitors are also present.  Secreted FRP directly binds to WNT and inhibit 
WNT signalling.  Dickkopf (DKK) is a multigene family comprising DKK1, DKK2, 
DKK3 and DKK4, each with two cysteine-rich domains.  If KREMEN1 or KREMEN2 is 
present, DKK1 is a potent WNT inhibitor by binding to LRP and promoting DKK-
mediated internalisation of LRP5/6, thus preventing WNT signalling.  If KREMEN is 
absent, DKK1 inhibition is weak.  If DKK1 is absent, KREMEN promotes localisation of 
LRP5/6 to the cell surface, thus promoting WNT signalling.
100
  DKK2 inhibits WNT 
signalling but is a weak activator of LRP5/6, so it can be an agonist if levels of LRP5/6 are 
high.
119
  DKK3 does not appear to modulate WNT signalling.  DKK4 is a WNT 
antagonist.
120
   
The β-catenin pathway can be activated without WNT.  Norrin, which does not show 
sequence similarity with WNT, binds to FZD4 and activates the β-catenin pathway.
121
 
3.2.5.  Non-canonical pathways 
The planar cell polarity (PCP) pathway mediates the polarisation of epithelial cells that 
occurs in orientations of hairs, fur, scales, feathers and cilia (such as the stereocilia in the 
cochlea), as well as convergent extension (narrowing and elongation of the tissue by cell 
movement).  It involves DVL and FZD but not LRP, β-catenin, or TCF.  FZD, as the name 
suggests, was discovered by its role in organising the hair and bristle pattern in the 
Drosophila.  WNTs do not play a role in PCP in the Drosophila, but there is evidence that 





pathway is a recently proposed pathway based on experiments in mainly 
Xenopus and zebrafish, where WNT binding to FZD may activate G proteins with release 
of intracellular calcium and activation of Ca
2+
 dependent effector molecules such as the 

















WNT can also signal via tyrosine kinase receptors, particularly RYK and ROR2.  These 
receptors have a cytoplasmic tyrosine kinase motif and have been found to interact with 
FZD.  RYK has a surface WNT inhibitory factor (WIF) ligand binding-domain that 
sequesters WNT away from binding to FZD.  It mediates axonal guidance in Drosophila 
and mammals, via WNT5-mediated activation of the SRC family of tyrosine kinases (in 
Drosophila)
125
 and/or WNT1-mediated FZD interaction with TCF activation (in 
mammals).
126
  ROR2 has a cysteine rich domain (CRD) which binds to WNT5A.  It 
influences convergence extension movements and inhibits TCF/β-catenin signalling in the 
nucleus, possibly through activating the mitogen-activated protein kinase JUN N-terminal 
kinase (JNK) (Figure 6).
127
 
3.2.6.  WNT target genes 
The WNT pathway targets more than 30 genes.  The genes activated depend on the type of 
WNT, the receptor it binds to, and the cross-talk that occurs between the different 
pathways.  Targeted genes include WNT pathway components for feedback control e.g. 
WNT signalling downregulates FZD and upregulates AXIN2 to inhibit WNT signalling.  
Genes involved in oncogenesis are also activated, such as MYC, cyclin D1, JUN, FOSL1 
(fra-1), matrilysin and members of the AP-1 family of genes (FOS, FOSB and JUNB).
128
 
MYC is a proto-oncogene encoding a nuclear transcription factor that activates genes 
involved in cell proliferation.  It can also reprogram somatic cells into pluripotent stem 
cells, enhance self-renewal, and block differentiation.  Persistent MYC expression is seen 
in many tumours.  MYC translocation is characteristic of Burkitt lymphoma.
129
  Cyclin D1 
is a cell cycle protein that binds to cyclin dependent kinases to form a complex that 
phosphorylates RB and allows the cell cycle to pass the G1-to-S transition.  Cyclin D1 is 
characteristically translocated in mantle cell lymphomas.
130
  Matrilysin is a matrix 
metalloproteinase, and may be involved in tumour invasiveness.  JUN and FOS are proto-
oncogenes whose products dimerise to form activator protein 1 (AP-1), a transcription 
factor involved in cell proliferation and apoptosis.
131
 
3.2.7.  Functions 
WNTs control organized cell movements, axis polarity, tissue polarity, stem cell 
maintenance, cell proliferation and cell fate.
100














developmental defects, while abnormalities in WNT pathways are implicated in cancers 
and degenerative diseases (Table 5). 
Table 5: WNT pathway genes and associated human diseases (modified from Logan & 
Nusse, 2004; Nusse, 2009)
101, 102
Gene (locus) Human disease 
WNT3 (17q21) Tetra-amelia
132
WNT4  (1p36) Müllerian-duct regression and virilisation (WNT4 inactivation) 
133
SERKAL (SEx Reversion, Kidneys, Adrenal and Lung dysgenesis) 
syndrome
134
WNT5B (12p13) Associated with susceptibility to type 2 diabetes mellitus
135
WNT7A (3p25) Fuhrmann and Al-Awadi/Raas-Rothschild/Schinzel phocomelia
syndromes
136
WNT10A (2q35) Odonto-onycho-dermal dysplasia (severe oligodontia, nail
dystrophy, palmoplantar hyperkeratosis and hyperhidrosis)
137




LRP5 (11q13) Abnormal bone densities
140, 141
Vascular defects in the eye: osteopetrosis-pseudoglioma syndrome
(OPPG),
140, 142






AXIN2 (17q23-q24) Tooth agenesis
145
Predisposition to colorectal cancer
145
APC (5q21) Polyposis coli, colon cancer
146
3.2.7.1.  Role in development 
During development, WNTs control gastrulation (formation of the 3 germ layers), early 
pattern formation and organogenesis.
99
  In the Xenopus, after fertilisation, WNT/β-catenin
signalling is relocated posteriorly (dorsally), allowing the establishment of the primary 
body axis pattern.
147

















In humans, WNT4 is critical in female gonadal differentiation and in the formation of the 
kidneys, adrenals, pituitary gland and mammary tissues.  Homozygous loss of function 
mutations of WNT4 causes various developmental abnormalities in humans.
133, 134
  WNT5B 





   
LRP5 is expressed in osteoblasts and is important in establishing bone mass.  LRP5 
mutations cause the autosomal recessive condition osteoporosis-pseudoglioma syndrome 
(with reduced bone mass in carriers)
140
 and various autosomal dominant conditions with 
increased bone density (such as osteopetrosis).
141
  LRP5 is also required for glucose and 
cholesterol metabolism and LRP5 polymorphisms are also associated with obesity.
144
   
DVL is important in cardiac organogenesis and neural tube closure and DVL-deficient 
mice display cardiac outflow tract defects and neural tube defects.
148
 
3.2.7.2.  Role in stem cell maintenance 
In general, WNT signalling prevents stem cell differentiation.  Whereas growth factors 
such as fibroblast growth factor and epithelial growth factor activate stem cell proliferation 
via tyrosine kinase receptors.
104
  Leucine-rich repeat-containing G protein-coupled receptor 
5 (LGR5) is a WNT target gene.  LGR5 is an adult stem cell marker that is expressed in the 
intestines, stomach, hair follicles and mammary gland and may be a universal marker for 
adult stem cells.
149
  WNT also plays important roles in wound repair.   
3.2.7.3.  Role in Cancer 
Constitutive activation of the WNT pathway is present in human cancers, particularly 
colorectal carcinomas.
146
  In colorectal carcinomas, mutations in APC was first identified 
in the familial adenomatous polyposis syndrome (FAP) but was subsequently found to be 
also present in up to 80% of sporadic colorectal carcinomas.
150
  Of the remaining 20%, half 
shows β-catenin mutations.
151
  Less commonly mutations in AXIN1 and AXIN2 have been 
identified.
152, 153
   
APC and β-catenin mutations are mutually exclusive and this phenomenon has also been 
observed in desmoid fibromatosis, an FAP-associated tumour.
154, 155
  Other sporadic 















adenocarcinomas, hepatoblastomas, medulloblastomas and pancreatoblastomas do not 
show APC mutations, but do show β-catenin mutations in a subset of cases.
154, 156
 
β-catenin mutations in colorectal carcinomas were associated with hereditary non-
polyposis coli syndrome (HNPCC).
152
  β-catenin mutations were also seen in ovarian and 
endometrial carcinomas (often of the endometrioid type), which are also associated with 
HNPCC.
157-159
  Approximately 90% of solid pseudopapillary tumours of the pancreas 
harbour β-catenin mutations, particularly in exon 3.
160
  Other tumours associated with 
mutations in β-catenin include pilomatricomas, ovarian borderline endometrioid tumours, 
anaplastic thyroid carcinomas, hepatocellular carcinomas and nephroblastomas.
154, 161
 
Upregulation of WNT/β-catenin pathway is seen in neuroblastomas,
162







 and malignant 
melanomas
128
. DVL1 is located on chromosome 1p36.  It has been proposed as a candidate 




During malignant progression in carcinomas where the tumour shows increased 
invasiveness, E-cadherin is downregulated during epithelial-mesenchymal transition, a 
process whereby individual carcinoma cells change from a cohesive epithelial phenotype 
to a motile mesenchymal phenotype and detach from the tumour mass to lie independently 
in the interstitium.
168
  Membrane E-cadherin loss occurs in breast lobular carcinomas, 
diffuse type gastric adenocarcinomas and a high proportion of renal cell carcinomas.
169
  
Membrane loss and/or nuclear expression is observed in solid pseudopapillary tumours of 
the pancreas.  Nuclear expression in pancreatic neuroendocrine tumours is associated with 

















3.3.  WNT AND ES/PNET 
The first study investigating WNT signalling in Ewing sarcoma was a RT-PCR study on 
nine Ewing sarcoma cell lines.
171
  In that study, it was determined that most cell lines 
express certain components of the WNT pathway (such as WNT5A, WNT10B, WNT11, 
WNT13, FZD 2, FZD3, FZD4, FZD7, FZD8 and LRP5/6) but not other components 
(WNT1, WNT2, WNT3, WNT3A, WNT7A, FZD1, FZD6, FZD9 and FZD10).  It was 
discovered that an intact WNT pathway is present in these cell lines, and that exogenous 
stimulation by WNT3A ligand causes markedly increased cytoplasmic β-catenin 
expression, 3-5 fold increase in cell chemotaxis, but no increase in cell proliferation.  β-
catenin immunohistochemical staining was also done on seven cases, all of which were 
negative.
171
  In view of the increased mobility, the authors of that study suggested that 
activation of WNT signalling may influence the metastatic potential of ES.   
Later on, WNT3A, DKK1, and treatment with LRP5/LRP6 short interfering RNA (siRNA) 
were found to enhance JNK activity and stimulate formation of neurites in ES cell lines; 
whereas neurite extension was reduced by treatment with FZD3 siRNA as well as 
knockdowns of DVL2 and DVL3.
172
 
Recent evidence shows that the EWS-FLI1 fusion protein activates the promoter region of 
DKK2 and represses the DKK1 promoter.
173
  EWS-FLI1fusion protein also binds to LEF1 
to inhibit β-catenin/TCF mediated transcription.
174
 
ES/PNET can display epithelial differentiation morphologically (adamantinomatous 
variant), immunophenotypically (cytokeratin expression) and ultrastructurally (cell 
junctions).  The nature of the cell junctions has been investigated immunohistochemically 
in 30 ES/PNET cases and appears to be tight junctions with frequent expression of claudin 
1 (63%), zonula occludens 1 (59%), and negativity for E-cadherin.
175
 
Markedly increased MYC expression has been reported in 10 of 13 ES/PNET cell lines 




Cyclin D1 expression has been reported in 13 of 13 ES/PNET cell lines
176
 and 13 of 31 
paraffin wax-embedded tissue specimens.
59















the EWS-FLI1 fusion protein.  Using cell lines, Matsumoto et al 
58
 demonstrated decreased 
cyclin D1 expression after repression of the EWS-FLI1 gene by using EWS-FLI1 antisense 
oligonucleotides, and increased cyclin D1 expression after EWS-FLI1 cDNA transfection.  




4.  MOTIVATION FOR CURRENT RESEARCH 
There are currently three immunohistochemical studies on WNT pathway components in 
ES/PNET reported in the current English language literature, including β-catenin in 7 cases 
of ES which did not show any significant cytoplasmic or nuclear staining
171
, E-cadherin in 
30 cases, all of which lack membranous staining
175
, and cyclin D1 immunoexpression in 
13 of 31 cases which did not show prognostic significance.
59
  All three studies targeted 
only isolated components of the WNT pathway without correlation with other components 
of the WNT pathway.  There was also very little, if any, clinicopathological correlation. 
Most investigations of the WNT pathway in ES/PNET attempted in the past were mainly 
performed on ES cell lines.  These studies suggested a repressed β-catenin pathway, 
although parts of the WNT pathway that are β-catenin independent may be active.
171-174
  
Past investigations also showed that the EWS-FLI1 fusion protein interacts with 
components of the WNT pathway.
59, 173, 174, 176
 
In view of the current literature suggesting a role for WNT signalling in ES/PNET, and the 
lack of comprehensive immunohistochemical studies of WNT components in ES/PNET 
with clinicopathological correlation, there exists a need for a comprehensive investigation 
of the expression of WNT pathway proteins in ES/PNET.  This may lead to a better 
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Aim:  To examine the immunohistochemical expression of the WNT pathway 
components in Ewing sarcoma (ES) / primitive neuroectodermal tumour (PNET)  
Method and results: Twenty five cases originally diagnosed with ES/PNET were 
retrieved from the archives and stained with antibodies against WNT1, WNT5A, DVL1, 
GSK3β, β-catenin, MYC, cyclin D1, E-cadherin (extracellular domain) and E-cadherin 
(cytoplasmic domain).  Of the 25 cases analysed, 23 cases were confirmed as ES/PNET 
on review.  Of the 23 cases, WNT1 was positive in 7 cases (30%), WNT5A in 12 cases 
(52%), DVL1 in 11 cases (48%), MYC in 11 cases (48%), cyclin D1 in 20 cases (87%), 
and nuclear localisation of the cytoplasmic domain of E-cadherin in 11 cases (48%).  
Nuclear β-catenin localisation was seen in 2 cases (8%).  Membranous E-cadherin 
staining was absent in all cases.  Except for an association of age with DVL1 and 
nuclear E-cadherin expression there was no statistically significant difference in the 
mean scores of the antibodies when segregated by clinicopathological parameters.   
Conclusion: WNT pathway components are expressed in a subset of ES/PNET, but 
seldom involve β-catenin nuclear localisation.  Cyclin D1 was frequently expressed. It 
may contribute to the proliferative potential of ES/PNET and may lead to the 
development of new therapeutic agents.  Lack of membranous E-cadherin is postulated 
as a contributory factor in the micrometastatic behaviour of ES/PNET.  The significance 
















Ewing sarcoma (ES) / primitive neuroectodermal tumours (PNET) are round cell 
sarcomas of probable CD133+ bone marrow-derived mesenchymal stem cell origin.
1, 2
  
They are characterised by varying but usually minimal degrees of neuroectodermal 
differentiation and almost always harbour a chromosomal translocation involving the 
Ewing sarcoma breakpoint region 1 gene (EWS or EWSR1) and a member of the ETS 
family of transcription factors (FLI1 in 85% of cases).
3-9
  They can occur in soft tissues 
and virtually any organ site, but are commonest in the bone, where they account for 6% 
of all bone malignancies in the Mayo Clinic files,
6
 and after osteosarcomas, are the 
commonest bone malignancy of childhood.
10
  
ES is traditionally distinguished from PNET based on the absence of neuroectodermal 
differentiation, which has no prognostic significance.
4, 11,10
  Based on cytogenetic 
findings, ES,  PNET and Askin tumour, a childhood malignant small cell tumour of 
thoracopulmonary origin,
12
 are grouped together as the ES family of tumours.
10
  PNET 
should be distinguished from supratentorial PNET, which is morphologically similar but 
lacks CD99 immunoexpression and EWS/FLI1 translocation.
13, 14
 
The differential diagnosis of ES/PNET includes other small round cell malignancies.  
Because numerous EWS-ETS fusion combinations are possible, reverse transcriptase 
polymerase chain reaction (RT-PCR) testing for the fusion transcripts may be less 
sensitive than fluorescent in situ hybridisation (FISH) testing for EWS translocations 
using EWS break-apart probes.
15
  However, EWS translocations also occur in myxoid 
round cell liposarcoma, acute myeloid leukaemia, clear cell sarcoma, angiomatoid 






ES/PNET is regarded as a micrometastatic disease from the outset,
18
 as without 
systemic chemotherapy fewer than 10% of patients survive even though the tumour is 
radiosensitive.
19
  With current combination of surgery, chemotherapy, and/or 
radiotherapy, the overall survival rate is 34% for patients with metastatic disease and 

















WNT proteins are a family of evolutionarily conserved, secreted ligands that guide the 
fate of the cells, from cell migration and morphogenesis in the embryo to stem cell 
maintenance and tissue homeostasis in the adult.
21, 22
  The complex functions are 
accomplished by having multiple WNT members (19 in humans)
23-25
 that bind to 
multiple receptors with activation of multiple interacting pathways.
24, 26
  WNT receptors 
include Frizzled (FZD), low-density lipoprotein receptor-related protein (LRP), and the 
transmembrane tyrosine kinases RYK and ROR2.
22, 27
  WNT pathways include the 
canonical and the non-canonical pathways.   
In the canonical pathway, secreted WNT binds to FZD and LRP 5/6 and recruits the 
cytoplasmic protein dishevelled (DVL) to prevent the adenomatous polyposis coli 
(APC)-glycogen synthase kinase 3β (GSK3β)-axin-casein kinase 1α (CK1α) protein 
complex from degrading cytoplasmic β-catenin.  Cytoplasmic β-catenin subsequently 
accumulates and translocates to the nucleus to induce transcription of WNT target genes 
such as MYC (also known as c-myc) and cyclin D1.
23, 28
  β-catenin also exists as a 
membrane bound form that links E-cadherin to α-catenin and the actin cytoskeleton.
29, 30
   
Abnormalities of the WNT/β-catenin pathway are present in many cancers, most 
notably colorectal carcinomas, in which APC mutation is the initiating event in more 
than 80% of sporadic colorectal carcinomas.
31-33
   
WNT pathway components have been investigated in neuroectodermal tumours.  Thirty 
six percent of supratentorial PNET have been reported to exhibit nuclear β-catenin 
immunolocalisation consistent with an active WNT/β-catenin signalling pathway, 
although β-catenin (CTNNB1) mutation was only identified in 4% of supratentorial 
PNET.
34
  Of note, nuclear β-catenin expression is associated with a trend towards longer 
patient survival in supratentorial PNET.
34
  In other neuroectodermal tumours, WNT5A 
underexpression in neuroblastomas
35
 and overexpression in malignant melanomas was 
found to be an indicator of poor prognosis.
36
  WNT proteins also play critical roles in 
bone formation
37
 and stem cell functioning.
38
  These findings raise the possibility that 
the WNT pathway may play a role in the biology of ES/PNET. 
To our knowledge, there are only three studies reported in the current English language 














The components tested include β-catenin in 7 cases of ES which did not show any 
significant cytoplasmic or nuclear staining,
39
 E-cadherin in 30 cases, all of which lack
membranous staining,
40
 and cyclin D1 immunoexpression in 13 of 31 cases.
41
  The last
study also found that cyclin D1 immunoexpression did not correlate with survival. 
With the exception of one study,
39
 the studies to date targeted only isolated components
of the WNT pathway.  Most of the studies did not correlate the expression of the 
individual components of the WNT pathway with each other.  There was also very little, 
if any, clinicopathological correlation.  In view of the relative lack of 
immunohistochemical testing and clinicopathological correlation in ES/PNET, this 
study was conducted to investigate more comprehensively the expression of WNT 
pathway proteins in ES/PNET by immunohistochemistry in order to understand the 
pathobiology of ES/PNET and potentially aid in its management. 
MATERIALS AND METHODS
From 1972 to 2008, 62 cases of ES/PNET were retrieved from the archives of the 
Division of Anatomical Pathology, University of Cape Town, Groote Schuur Hospital, 
Red Cross War Memorial Children’s Hospital and Anatomical Pathology Laboratory
Greenpoint, Cape Town. All haematoxylin and eosin (H&E) and 
immunohistochemically stained slides were reviewed to confirm the original diagnosis.  
Of the 62 cases, 25 cases with sufficient tissue available were selected and an 
appropriate tumour block selected for immunohistochemical staining.  Blocks with no 
or minimal tumour necrosis were preferred. 
Antibodies 
The following primary antibodies were used (Table 1): WNT1, WNT5A, DVL1, 
GSK3β, β-catenin, MYC, cyclin D1, E-cadherin extracellular domain (36B5), and E-
cadherin cytoplasmic domain (36/E-cadherin).   
Staining procedure 
Paraffin-wax embedded tissue sections were stained according to the following 
procedure: 2-3μm sections were floated onto 3-aminopropyltriethoxysilane coated glass 
slides and incubated overnight at 60 °C to adhere sections to slide.  Sections were 















then blocked for endogenous peroxidase in 3% H2O2 water solution for 5 minutes, and 
after washing in water, heat-induced antigen retrieval was performed by pressure 
cooking slides at full pressure in either 0.01M citrate buffer (pH 6) for 2 minutes or 
EDTA (pH8) for 1 minute (Table 1).   Antigen retrieval was optimised for optimal 
intensity and clarity of staining.  After antigen retrieval sections were rinsed in 
phosphate buffered saline (PBS) pH 7.6 and then blocked for non-specific binding using 
a 5% goat serum solution at room temperature for 10 minutes (Dako X0907).  The goat 
serum was drained off and the sections were incubated with the primary antibody at 
room temperature for specified durations (Table 1).  
After incubation, the sections were washed in PBS and then treated with goat anti-
mouse immunoglobulin labelled with horseradish peroxidase (Envision: Dako K4001) 
at room temperature for 30 minutes.  Sections were washed in PBS.  Positivity was 
developed by applying 3,3'-diaminobenzidene (DAB, Dako K3466) at room 
temperature for 5-10 minutes. Sections were washed in water and immersed in a 1% 
CuSO4 solution for 5 minutes to enhance DAB staining.  Slides were counter-stained in 
an aqueous haematoxylin solution with “bluing” of nuclei performed using Scott’s tap 
water, followed by dehydration using graded ethanols, clearing with xylene before 
mounting with rapid mountant medium. 
A negative control, in which the primary antibody was replaced by PBS (buffer), was 
run simultaneously.  A positive external control was used for each antibody using 
tissues recommended by the manufacturer when possible (Table 1).  
Grading of staining 
β-catenin immunostaining was scored according to the protocol used by Jass et al.
42
   
This protocol scores 1 for loss of cell membrane staining, 1 or 2 for slight and 
pronounced increase in cytoplasmic staining, respectively, and 1 or 2 for slight and 
pronounced nuclear staining, respectively, giving a maximum score of 5.  Cases scoring 
4 or more were regarded as positive for abnormal β-catenin immunolocalisation.  
For the other antibodies the immunostaining score was based on the protocol used by 
Chetty et al.
43
  The scoring was as follows: moderate and/or strong immunolabelling 














negative), less than 5% tumour cells stained; a score of 1 (or focal positivity), 6% to 
50%; and a score of 2 (or diffuse positivity), more than 50%.  In addition, the cellular 
location of the immunoreactivity was noted.  
Clinical and pathological correlation 
The immunoscores of each antibody were segregated into 2 subgroups in each clinical 
and morphological category as follows: age (≤ 12 / > 12 years of age), gender (male / 
female), site (skeletal / extraskeletal), location (central / peripheral), metastasis (present 
/ absent), mitotic count (≤ 10 / > 10 mitoses per 10 high power fields [HPF]), nucleoli 
(inconspicuous / prominent), and neuroectodermal differentiation (present / absent).   
The subgroups were then compared using the two-sample Wilcoxon rank-sum (Mann-
Whitney) test since these data were not normally distributed.   
The relationship between the antibodies was analysed by comparing the mean 
immunoscores of an antibody by those of another antibody. The Kruskall-Wallace
equality of rank test with ties was used since the comparisons involved more than two 
means.  
A p-value of less than 0.05 was used as the standard cut-off for statistical significance
for all the analyses.  All analyses were performed using Stata 11.1 (StataCorp LP, 4905 
Lakeway Drive, College Station, TX 77845, USA).
RESULTS
On review 2 cases were found to be misdiagnosed as ES/PNET.  One case showed a
fibrillary background, CD99 negativity, and diffuse and strong synaptophysin positivity
consistent with a neuroblastoma.  The other case showed a linear pattern of infiltration 
suspicious for lymphoblastic lymphoma, which was confirmed by positive
immunostaining for terminal deoxynucleotidyltransferase (TDT).  
Of the remaining 23 cases, 22 cases were biopsy specimens and 1 case a resection 
specimen.  The age range was 2-43 years (mean age = 11 years).  There was a male 
preponderance (male : female  = 1.3:1).  Fourteen of the 23 cases (61%) were of mixed 















Eleven cases had an osseous primary, 11 extraosseous (including 2 cases of Askin 
tumours), and 1 undetermined (metastatic ES/PNET without information on the primary 
site).  Ten cases were located in the trunk, 2 in the head and neck, 10 in the extremities, 
and 1 unknown.  The biopsy specimen was taken from the primary tumour in 21 
patients, and from the metastatic deposit in 2 (one of which had a known primary in the 
femur).  At least 3 cases received chemoradiation prior to histological examination.  At 
least 4 cases were known with metastatic disease. 
Six cases (26%) showed neuroectodermal differentiation (Homer-Wright rosettes) and 
were classified as PNET.  Of those without neuroectodermal differentiation, 2 cases 
(9%) were classified as Askin tumour based on their thoracopulmonary location.  The 
remaining 15 cases (65%) were classified as ES.  The highest mitotic count was 19 
mitoses per 10 HPF with a mean of 2 mitoses per 10 HPF.  Nucleoli were absent or 
inconspicuous in 17 cases (74%), and distinct or prominent in 6 cases (26%).  CD99 
positivity was present in all cases, usually in a membranous distribution (Figure 1A). 
WNT1 immunoscores were 0 in 16 cases (70%), 1 in 4 cases (17%), and 2 in 3 cases 
(13%).  The mean score was 0.43 (95% confidence interval being 0.12-0.75).  Of the 
cases scoring 1 or more, the staining was membrane and cytoplasmic in 4 cases, and 
cytoplasmic only in 3 cases (Figure 1B).  Nuclear membrane staining was noted in 6 
cases and was regarded as aberrant staining that did not count towards scoring.  
WNT5A immunoscores were 0 in 11 cases (48%), 1 in 3 cases (13%), and 2 in 9 cases 
(39%).  The mean score was 0.91 (0.50-1.32).  Staining was cytoplasmic in all cases 
(Figure 1C).   
DVL1 immunoscores were 0 in 12 cases (52%), 1 in 3 cases (13%), and 2 in 8 cases 
(35%).  The mean score was 0.83 (0.42-1.23).  Staining was cytoplasmic in all cases 
(Figure 1D).   
GSK3β immunoscores were 0 in 13 cases (52%), 1 in 2 cases (13%), and 2 in 8 cases 
(35%).  The mean score was 0.78 (0.37-1.19).  Staining was cytoplasmic in all cases 















β-catenin immunoscores were 1 in 6 cases (26%), 2 in 9 cases (39%), and 3 in 8 cases 
(35%).  None scored 4 or more (the positive cut-off point).
42
  The mean score was 2.09 
(1.74-2.43).  Cytoplasmic only staining was present in 13 cases (Figure 1F), 
membranous and cytoplasmic staining in 3 cases, nuclear and cytoplasmic staining in 1 
case, and nuclear only staining in 1 case (Figure 1G).  The remaining 5 cases (22%) 
were negative for β-catenin.  Membranous staining was lost in 20 cases (87%). 
MYC immunoscores were 0 in 12 cases (52%), 1 in 7 cases (31%), and 2 in 4 cases 
(17%).  The mean score was 0.65 (0.32-0.99).  Staining was cytoplasmic with 
paranuclear localisation (Figure 1H).   
Cyclin D1 immunoscores were 0 in 3 cases (13%), 1 in 3 cases (13%), and 2 in 17 cases 
(74%).  The mean score was 1.61 (1.30-1.92).  Staining was nuclear in all cases (Figure 
1I). 
There was no membranous E-cadherin staining with both the 36B5 clone and the 36/E-
cadherin clone in all cases (100%).  Unlike the 36B5 clone, the 36/E-cadherin clone 
showed nuclear staining (Figure 1J), with a score of 0 in 12 cases (52%), a score of 1 in 
1 cases (4%), and a score of 2 in 10 cases (44%).  The mean score was 0.91 (0.48-1.34).   
DVL1 scores were significantly increased in cases from patients older than 12 years of 
age, with a mean score of 0.42 in patients ≤ 12 years of age, and a mean score of 1.3 in 
patients > 12 years of age (p=0.032).  The mean nuclear E-cadherin score was 
significantly higher in cases from patients younger than 12 years of age, being 1.41 in 
patients <12 years of age and 0.4 in patients ≥ 12 years of age (p=0.017).  There was no 
statistically significant difference in the mean scores of the other antibodies when 
correlated with clinicopathological parameters  
The mean scores of WNT1 were increased with increasing DVL1 scores (p=0.0315) and 
with increasing MYC (p=0.0201) scores.  WNT5A scores were increased with 
increasing GSK3β scores (p=0.0247).  DVL1 scores were increased with increasing 
WNT5A (p=0.0182) and GSK3β (p=0.0255) scores.  GSK3β scores were increased with 
increasing WNT5A (p=0.0231) and DVL1 (p=0.0203) scores.  Cyclin D1 scores were 















E-cadherin immunoscores do not show a statistically significant correlation with other 
antibodies, although the 2 cases with β-catenin nuclear translocalisation both showed a 
high WNT5A score of 2.  
DISCUSSION 
The sample population had a mean age of 11 years.  Although this is less than the mean 
age of 15 years reported by the United States Surveillance Epidemiology and End 
Results (SEER) program,
44
  our study population was not consecutive and was biased  
by paediatric cases.  The male : female ratio of 1.3:1 of the sample population is similar 
to the male : female ratio of 1.4:1 reported by the SEER program.  The majority (61%) 
of the sample population was of mixed ancestry, probably related to local population 
demographics.  African race was uncommon (4%), a finding also reported by the SEER 
program, but our study population was biased by spanning a period of time where the 
hospitals were limited to certain population groups. 
CD99 expression was 100% in our sample, comparable with the CD99 positivity of 90 
to 100% reported by the literature.
4, 45-47
  It is acknowledged that the lack of molecular 
confirmation is a short-coming in this study. 
Most investigations of the WNT pathway in ES/PNET were on ES/PNET cell lines.  A 
RT-PCR study on 9 ES/PNET cell lines found expression of certain components of the 
WNT pathway (WNT5A, WNT10B, WNT11, WNT13, FZD 2, FZD3, FZD4, FZD7, 
FZD8 and LRP5/6) but not others (WNT1, WNT2, WNT3, WNT3A, WNT7A, FZD1, 
FZD6, FZD9 and FZD10).  The investigators of that study concluded that there was 
evidence that an intact WNT signalling pathway existed in ES/PNET cell lines and 
suggested that WNT appeared to modulate cell motility.
39
  Unlike that study, our study 
showed WNT1 immunostaining in 7 cases, possibly because of larger sample size.   
WNT1 immunostaining in our sample correlated with DVL1 and MYC immunostaining.  
This may suggest an intact canonical WNT pathway in a subset of ES/PNET cases, but 
there was no β-catenin nuclear translocalisation in the WNT1 positive cases.  One of the 
WNT1 negative cases with nuclear β-catenin expression showed nuclear membrane 
expression of WNT1 in 5% of the tumour cells.  The cause for the nuclear membrane 















The anti-tumoural effect of WNT1 blockade has been reported in a human 
neuroblastoma cell line (using WNT1 RNAi)
48
 and human hepatoma cell lines (using 
anti-WNT1 antibody).
49
  Investigation of the effects of WNT1 blockade in ES/PNET 
has not been done but may be of some value. 
WNT5A has been reported to modulate GSK3β to phosphorylate ROR2 to activate the 
WNT-JNK pathway (a non-canonical pathway).
50
  In our study, WNT5A 
immunostaining correlated with GSK3β immunostaining. This suggests the presence of 
non-canonical WNT signalling in a subset of ES/PNET.  WNT1 and WNT5A 
immunostaining did not seem to correlate with each other.  The canonical and non-
canonical WNT signalling pathways may not be dependent on each other and may be 
mutually exclusive in our study population.  WNT5 mediates axonal guidance in 
Drosophila via the RYK receptor
51
 but there was no association between WNT5A 
scores and neuroectodermal differentiation in this study.   
Antitumoural effects of WNT5A blockade has been reported in pancreatic carcinoma 
and melanoma xenografts in mice (using phenylmethimazole)
52
 and also in melanoma 
cell lines (using Wnt5a-derived N-butyloxycarbonyl hexapeptide).
53
 
DVL1 has not been investigated in ES/PNET previously, but knockdown of DVL2 and 
DVL3 in ES cell lines has been reported to suppress neurite outgrowth.
54
  There was, 
however, no statistically significant correlation between DVL1 expression and lack of 
neuroectodermal differentiation in our study.  DVL1 overexpression has been observed 
in lobular carcinoma of the breast.
55
  Interestingly, lobular carcinomas, similar to 
ES/PNET, characteristically lack membranous E-cadherin expression.  
GSK3β immunostaining correlated with WNT5A and DVL1 expression.  This may 
indicate inhibition of the canonical WNT signalling in a subset of ES/PNET cases.  
GSK3β affects both the canonical and non-canonical pathways.  In the canonical 
pathway it phosphorylates β-catenin and marks β-catenin for degradation.  In the non-

















None of our cases had a β-catenin score of ≥ 4.  EWS-FLI1 represses β–catenin 
signalling
56
 and may account for the rarity of nuclear β–catenin expression as well as
the lack of association between β–catenin and WNT1 and DVL1 expression in this 
study.  The 2 cases with nuclear β-catenin translocalisation both showed strong WNT5A 
immunostaining.  WNT5A can inhibit β-catenin signalling if the receptor ROR2 is 
present.  It can also activate β-catenin signalling if FZD4 is present,
57
  and FZD4
expression has been reported in ES/PNET cell lines.
39
  It is possible that FZD4 may
play a role here.   
Cyclin D1 immunostaining was not significantly associated with WNT1, WNT5A, 
DVL1, GSK3β or β-catenin immunostaining.  This may be because cyclin D1 promoter 
is a downstream target of the ETS family members,
41
with repression of the EWS-FLI1
fusion gene using EWS-FLI1 antisense oligonucleotides resulting in decreased cyclin 
D1 expression, and EWS-FLI1 cDNA transfection resulting in increased cyclin D1 
expression.
58
Cyclin D1 is a cell cycle protein that allows the cell cycle to pass the G1-to-S 
transition.
59
However, despite high cyclin D1 immunostaining in cases with a high 
mitotic count, the association was not statistically significant (p=0.16).  WNT5A and 
nuclear E-cadherin were also weakly associated with increased proliferation (p=0.10 
and p=0.11 respectively), but the underlying mechanisms are yet to be unravelled.  The
4 cases with metastatic disease all showed a cyclin D1 immunoscore of 2, but the
metastatic group was small and statistical analysis failed to show significance.  Cyclin 
D1 immunostaining was associated with nuclear E-cadherin staining in our study.  Of
interest, solid pseudopapillary neoplasms of the pancreas also co-express nuclear E-
cadherin and cyclin D1.
60, 61
However, unlike our sample, most solid pseudopapillary
neoplasms show nuclear β-catenin expression.
Flavopiridol (alvocidib) is a cyclin dependent kinase inhibitor. Administration has been 
found to result in significant clinical response in a phase II trial for relapsed chronic 
lymphocytic leukaemia
62

















MYC was associated with WNT1 immunostaining.  It is a downstream target of the 
canonical pathway but is also upregulated by EWS-FLI1.
64
  MYC is a proto-oncogene 
encoding a nuclear transcription factor that activates genes involved in cell proliferation, 
self-renewal, and reprogramming of somatic cells into stem cells.  Increased MYC has 
been reported in 10 out of 13 ES/PNET cell lines using Western blot.
64
  However, in our 
study, MYC expression was only seen in 48%, possibly because the intensity of MYC 
immunostaining was only moderate at best.  There was no significant association 
between MYC expression and mitotic activity in our study; possibly because cyclin D1 
was already upregulated.  
Drugs targeting MYC are under development and testing.
65
  Quarfloxin is a G-
quadruplex (four-stranded DNA structure) that targets the MYC promoter and was in 
phase 2 clinical trials for neuroendocrine/carcinoid tumours, but has now been 




Membranous E-cadherin expression was absent in our cases, confirming the finding of a 
previous study which reported negative E-cadherin immunoexpression in ES/PNET.
40
  
That study also reported variable expression of tight junction markers (claudin-1, 
occludin, zonula-occludens-1) in ES/PNET, consistent with the ability of ES/PNET to 
show partial epithelial differentiation.  Although E-cadherin competes with APC for 
binding to β-catenin, loss of E-cadherin does not normally cause nuclear β-catenin 
accumulation because cytoplasmic β-catenin is normally degraded by the APC-GSK3β-
axin-CK1α complex.  However, if canonical WNT signalling is present, β-catenin is no 
longer degraded, and a lack of membranous E-cadherin may then increase cytoplasmic 
β-catenin.
67
  This may account for the frequency of cytoplasmic β-catenin staining in 
our study.  Membranous β-catenin is rare in our sample, possibly due to the lack of 
membranous E-cadherin to which β-catenin is normally anchored to.  The lack of 
membranous E-cadherin expression has been postulated to play a role in the 
micrometastatic propensity of carcinomas
68
 and may potentially also play a role in that 
of ES/PNET.  Overexpression of membranous E-cadherin has been reported to cause 
G1-S phase arrest and apoptosis by interfering with β-catenin signalling in epithelial 
cells.
69















downregulation of cyclin D1 and  reduced proliferative activity
70
 but is also associated 
with reduced apoptosis and increased chemoresistance.
71
 
Nuclear expression of E-cadherin in ES/PNET has not been reported previously in the 
English language literature.  With regards to other tumours, nuclear E-cadherin 
expression has been seen in synovial sarcomas,
72
 Merkel cell carcinomas,
73
 various 
carcinomas (colorectal, oesophageal, clear cell renal cell carcinomas) and pancreatic 
endocrine tumours, and all solid-pseudopapillary tumours of the pancreas.
74, 75
  The 
mechanism for nuclear localisation of E-cadherin is uncertain and appears to be 
independent of β-catenin
75
 but dysregulation of p120 is a postulated mechanism.
76
  
While nuclear E-cadherin expression did not correlate with β–catenin immunostaining 
in our study, nuclear E-cadherin may bind nuclear β-catenin and prevent it from binding 
to transcription factors.
77
   
CONCLUSION 
This study demonstrated expression of the WNT pathway components in a cohort of 
patients with ES/PNET, but nuclear β–catenin immunolocalisation was rare, suggesting 
a repressed canonical pathway.  Non-canonical pathways may still have a role to play in 
ES/PNET.  Despite rare nuclear localisation of β-catenin, expression of the targets of 
the canonical pathway such as cyclin D1 and MYC were common, most likely related to 
alternative upregulation of the e targets by the ETS family of transcription factors.  
Cyclin D1, MYC, WNT5A and WNT1 may be potential targets for therapy.  All cases 
of ES/PNET were negative for membranous E-cadherin, which may be a possible 
mechanism contributing to the micrometastatic ability of ES/PNET.  A subset of 
ES/PNET also showed nuclear E-cadherin expression, the significance of which 
remains to be elucidated.  
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Figure 1: Immunohistochemical results.  A: Membranous CD99 expression, 200x.  B: 
WNT1 cytoplasmic expression, 200x.  C: WNT5A cytoplasmic expression, 200x.  D: 
DVL1 cytoplasmic expression, 200x.  E: GSK3β cytoplasmic expression, 200x.  F: 
Cytoplasmic β-catenin, 200x.  G: Nuclear β-catenin expression, 200x.  H: MYC 















Table 1: Primary antibodies. 
Primary 
antibody 




























Novo-castra EDTA 1:400 120 Burkitt 
lymphoma 
Cyclin D1 SP4 
(monoclonal) 
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PART D: SUPPORTING DOCUMENTS 
1.  TABLES 
 
Table 1: Clinical features. 
No. Race Sex Age Site Diagnosis Clinical data 
1 W F 10 Unknown Metastatic ES 
(from skeletal 
ES of right 
proximal 
femur) 
Presented at age 4 with tumour right 
thigh, biopsy diagnosis favoured 
neuroblastoma, differential diagnosis 
ES. Lung biopsy 2 year and 1 month 
later confirmed metastatic tumour. 
Hindquarter amputation performed 8 
month later (probably post-radiation) 
showed 90% necrosis, tumoural 
calcification and negative lymph nodes. 
Lymph node biopsy 8 month later 
showed metastatic tumour. Biopsy of a 
metastatic deposit (current case) 3 
years later at the age of 10 confirms the 
diagnosis of a metastatic ES. 
2 W M 6 Chest wall Askin tumour Anterior mediastinal tumour eroded 
through anterior chest wall – probably 
arising in the chest wall. 




Tumour dorsum right foot said to be 
present since birth. Excisional biopsy 
of large tumour within extensor 
digitorum brevis.  
4 C M 10 Left leg 
(tibia 
diaphysis) 
Skeletal PNET No clinical data 
5 C M 6 Bone Skeletal ES No clinical data 
6 C F 6 Left tibia Neuroblastoma Osteitis not settling. ? tumour left tibia 
7 W F 11 Right thigh Extraskeletal 
ES 
Rigth thigh mass; cyst excised from 
subcutaneous tissue 
8 W F 6 Left leg Extraskeletal 
ES 
Sent in as recurrent ES 
9 C M 2 Post neck Extraskeletal 
PNET 
Four month swelling in subcutaneous 
tissue of low occipital region 
10 W M 8 Left tibia Lymphoblastic 
lymphoma 
Query chronic osteomyelitis left tibia 
11 C M 11 Right lung Metastatic ES Multiple coin-shaped lesions in right 
lung, also multiple lytic bone lesions. 
Primary unknown. 




Thoracic extradural mass; urinary HVA 















chemotherapy; case used = pre-therapy 
biopsy; post-therapy biopsy not 
available for review 
13 W F 7 Left rib Skeletal PNET Neoadjuvent therapy given 
Moderately pleomorphic small ovoid 
cells with distinct nucleoli;  
14 C M 19 Left 
proximal 
fibula 
Skeletal ES MRI favoured Ewing sarcoma. Last 
blood result in 2003. Patient deceased. 
Folder withdrawn in 2008. 
15 C F 10 Right ileum Skeletal ES Large tumour right ileum 




Spinal tumour, progressive back pain 
for 1 month associated with lower limb 
weakness and loss of perianal 
sensation. MRI showed spinal cord 
compression at T10-11 by extradural 
mass. Pleural biopsy 2 years later 
confirmed metastatic disease. 




Small cell carcinoma diagnosed at 
around age 28, had chemotherapy, now 
large lesion right lung apex invading 
vertebral body and dura 
18 C M 19 Left 
proximal 
femur 
Skeletal PNET Query osteosarcoma with bone 
destruction. Biopsy in 2001. Last blood 
result in 2003 showed hypercalcaemia. 
Patient’s folder withdrawn in 2007. 
19 C M 24 Tibial 
diaphysis 
Skeletal ES 
with soft tissue 
extension 
Painful swelling R calf for 1 year; 10 x 
8cm hard, fixed mass medial aspect of 
right calf. MRI shows calf mass 
encasing peroneal and posterior tibial 
neurovascular bundles. Initial CT chest 
showed four small lung nodules 
interpreted as metastatic disease (post-
chemotherapy CT showed decrease in 
size of the nodules). Bone scan and 
marrow biopsy negative for metastasis. 
Neo-adjuvant chemotherapy 
(ifosfamide, etoposide) with good 
clinical response (significant decrease 
in primary tumour size on MRI); 
through  knee amputation 3 months 
after biopsy showed tumour involving 
soft tissues and tibial cortex without 
medullary involvement. Vascular 
invasion was present. There was no 
post-chemotherapy tumour necrosis. 
Patient alive but lost to follow up 1 
year 5 months (last discharged 
27/10/2009 TCB in 3/12) after initial 
presentation (07/05/2008). 
20 B F 14 Ankle Extraskeletal 
ES 















21 C M 32 Chin Extraskeletal 
ES 
Rapidly enlarging mass on tip of chin 
22 C F 43 Left femur Skeletal ES  Pathologic fracture left femur 
23 W F Unknown Pelvis Skeletal ES Pelvic mass, query Ewing sarcoma 
24 W M 27 Right chest 
wall 
Askin tumour  Right chest wall mass, 10 x 10cm 
25 W F 17 Acetabulum Skeletal PNET Tumour right hemipelvis; MRI query 
ES / chondrosarcoma / osteosarcoma 
No., case number; W white, B black, C coloured (mixed ancestry), F, female; M, male; 


















Table 2: Pathologic characteristics. 
No. Diagnosis Morphology Nucleoli MF PAS CD99 Other investigations 
1 Metastatic ES  Uniform small cells  none 0 None + EMA-, NB-, CD68-, LCA-. 
2 Askin tumour Alveolar growth pattern distinct 0 Abundant +  myoglobin+ (reported-), desmin weak + (reported-), CK-, 
EMA-, LCA-, S100-, SMA-, MSA- 
3 Extraskeletal 
ES 
Uniform medium sized cells inconspicuous 15 Scant +  EM desmosome-like structures, focal glycogen, abundant 
polyribosomes, poorly developed organelles, no secretory 
granules. 
4 Skeletal PNET Homer-Wright rosettes present none 16 Scant + NB-, desmin-, myoglobin-, SMA-; EM: neurosecretory 
granules. 
5 Skeletal ES Uniform small cells none 0 None +  
6 Neuroblastoma Moderately pleomorphic, fine 
chromatin  
inconspicuous 1 None - (CD99 
repeated) 
Synaptophysin strongly and diffusely positive 
7 Extraskeletal 
ES 
Moderately pleomorphic, coarse 
chromatin  
distinct 8 Scant + LCA-, CD30-, CD3-, CD20-, S100-, desmin-, MYF4- 
8 Extraskeletal 
ES 





inconspicuous 14 None +  NSE+ vimentin+, S100+; CK-, LCA- 
10 Lymphoblastic 
lymphoma 
Uniform small cells none 0 None +  TDT+ 
11 Metastatic ES Moderately pleomorphic, 
vesicular chromatin 
inconspicuous 12 Scant +  LCA-, SMA-, CD68-, NB-, EMA - 
12 Extraskeletal 
PNET 
Uniform medium sized cells, 
dispersed chromatin 
none 0 Not done + NSE weak +, neurofilament +; chromogranin+/-; NB-, S100-, 
LCA-, CD68-; EM microtubules, primitive junctional 
complexes 
13 Skeletal PNET Moderately pleomorphic small 
ovoid cells Homer-Wright 
rosettes present 
distinct 2   + S100+, vimentin+; GFAP-, NSE-, desmin-; EM shows long 
cytoplasmic processes, neurotubules, abundant glycogen in 
some cells, no neurosecretory granules 
14 Skeletal ES Small round to oval cells, dense 
chromatin 


















15 Skeletal ES Uniform small cells distinct 4 Scant + desmin-, NB84-, NF- 
16 Extraskeletal 
ES 
Uniform medium sized cells inconspicuous 17  None + CD56+, S100+; NF-, MNF-, AE1/AE3-, EMA-, CK7-, Melan 
A-, HMB45-, LCA-, TDT-, inhibin-, CD34-, CD43-, MYF4-, 
CD30-, neurofilament-, chromogranin-, PGP9.5- 
17 Extraskeletal 
ES 
Uniform medium sized round 
cells 
inconspicuous  11 Not done +  Vimentin+; Cam 5.2-, MNF-, TTF1-, CD10-, CD56-, desmin-, 
calponin-, MYF4-, synaptophysin-. 
18 Skeletal PNET Moderately pleomorphic angular 
to spindled cells, vesicular 
chromatin, Homer-Wright 
rosettes. 
inconspicuous 19 Scant +  vimentin+, CD117+; LCA-, desmin-, MSA-, MyoD1-, NSE-, 
S100-, synaptophysin-, NB74-, chromogranin-, CD56-. EM: 
primitive cells with neuritic processes and occasional glycogen 
19 Skeletal ES Uniform small cells inconspicuous 0 Abundant + CK7-, EMA-, LCA-, desmin-, MyoD1-, NSE weakly + 
20 Extraskeletal 
ES 
Uniform medium sized cells, 
stippled chromatin 
inconspicuous 11 Scant +  vimentin+, Bcl2+, EMA-, MNF116-, CK7-, E-cadherin-, S100-
, synaptophysin-, CD56- 
21 Extraskeletal 
ES 
Uniform medium sized cells, 
vesicular chromatin 
prominent 19 Moderate +  vimentin+, Cam5.2-, MNF116-, CD20-, NSE-, desmin- 
22 Skeletal ES Moderately pleomorphic, 
vesicular chromatin 
distinct 3   + Vimentin+, NSE+; Cam5.2-, CK7-, CK20-, TTF1-, CD43- 
23 Skeletal ES Uniform small cells, dispersed 
chromatin 
none 2 None + AE1/AE3-, desmin-, myf4-, LCA-, S100- 
24 Askin tumour Uniform small cells, dense 
chromatin 
none 0 None +  Vimentin focally +; Cam5.2-, desmin-, MyoD1-, LCA-, S100-, 
chromogranin- 
25 Skeletal PNET Uniform medium to large cells, 
fine chromatin, Homer-Wright 
rosettes are prominent 
inconspicuous  0 Abundant +  MNF116 isolated +,  S100 isolated +, synaptophysin-, NB84 + 
No., case number; MF, mitoses per 10 high power fields; +, positive; -, negative; +/-, equivocal; CK, pancytokeratin; EMA, epithelial membrane 

















Table 3: Immunohistochemical scores and immunolocalisation. Case 6 and case 10 were 
not ES/PNET on review and were excluded from statistical analysis.  
No. WNT1 WNT5A DVL1 GSK3β β-catenin MYC Cyclin D1 E-cadherin 
1 0 C 0 C 0 A 0 C 1 A 1 P 2 N 0 A 
2 0 NM 1 C 2 C 2 C 2 C 1 P 2 N 2 N 
3 0 M 0 A 0 A 0 A 1 A 2 P 2 N 2 N 
4 1 M,C 2 C 0 A 2 C 3 C 1 P 2 N 2 N 
5 1 C 0 C 0 A 0 C 1 M,C 0 A 1 N 0 N 
6 0 A 0 A 0 A 1 C 1 A 0 A 0 A 0 A 
7 0 NM 2 C 2 C 2 C 2 C 0 P 2 N 2 N 
8 0 NM 0 A 0 C 0 A 3 C 0 P 0 N 1 N 
9 0 NM 2 C 0 C 0 C 3 N,C 0 P 2 N 2 N 
10 0 A 0 C 0 A 0 A 1 A 0 A 0 A 0 N 
11 0 A 0 C 0 A 1 C 2 C 0 A 2 N 2 N 
12 0 A 1 C 1 C 0 A 2 C 0 A 1 N 0 A 
13 0 A 0 A 0 A 0 A 2 C 0 A 2 N 2 N 
14 0 A 0 A 0 A 0 C 3 C 2 P 2 N 0 A 
15 0 M 0 C 0 A 0 C 2 C 0 A 2 N 2 N 
16 1 M,C 2 C 2 C 2 C 3 C 1 P 2 N 2 N 
17 2 C 2 C 2 C 2 C 2 M,C 1 P 2 N 0 A 
18 0 A 2 C 0 C 0 A 1 A 0 A 2 N 0 A 
19 2 M,C 2 C 2 C 2 C 3 C 2 P 2 N 0 A 
20 0 NM 2 C 2 C 1 C 2 C 0 A 2 N 2 N 
21 2 C 0 A 2 C 0 C 2 M,C 1 P 1 N 0 A 
22 0 C 2 C 1 C 2 C 3 N 2 P 0 N 0 A 
23 0 NM 0 A 1 C 2 C 1 A 0 P 2 N 0 A 
24 0 A 0 A 0 A 0 A 1 A 0 A 0 A 0 A 
25 1 M,C 1 C 2 C 0 C 3 C 1 P 2 N 0 A 
No., case number; NM nuclear membrane; A completely absent staining; C cytoplasmic; 
M membrane; N nuclear; P paranuclear. Membranous E-cadherin was negative in all cases.  
Nuclear E-cadherin staining is only seen with the antibody against the cytoplasmic domain 
















Table 4: Comparing immunohistochemical scores using clinical parameters (two-sample 
Wilcoxon rank-sum test).  A p-value of less than 0.05 is statistically significant. 




WNT1 0.0651 0.0558 0.9284 0.8994 0.3418 
WNT5 0.1212 0.3406 0.3557 0.2639 0.8587 
DVL1 0.0315 0.9452 0.1133 0.5138 0.7193 
GSK3β 0.4278 0.7252 0.8601 0.7108 0.2504 
β-catenin 0.3409 0.6439 0.8080 0.3972 0.6348 
MYC 0.0777 0.6822 0.5078 0.1713 0.2842 
Cyclin D1 0.7044 0.7473 0.4832 0.7527 0.2062 

















Table 5: Comparing immunohistochemical scores using pathologic features (two-sample 






WNT1 0.9312 0.5171 0.2284 
WNT5A 0.1914 0.8177 0.0970 
DVL1  0.3324 0.2952 0.8615 
GSK3β 0.1648 0.5517 0.5922 
β-catenin  0.3710 0.8521 0.9199 
MYC 0.2808 0.9386 0.8083 
Cyclin D1  0.4670 0.6494 0.1643 
















Table 6: Comparing immunohistochemical scores with each other (chi-squared test with 
ties).  A p-value of less than 0.05 is statistically significant. 
Antibody WNT1 WNT5A DVL1 GSK3β β-catenin MYC Cyclin-D1 E-cadherin 
WNT1 0.0001 0.4578 0.0315 0.2632 0.4200 0.0201 0.2131 0.3511 
WNT5A 0.4579 0.0001 0.0621 0.0247 0.1226 0.6545 0.4341 0.4969 
DVL1 0.0557 0.0182 0.0001 0.0255 0.1066 0.1301 0.6372 0.6092 
GSK3β 0.4727 0.0231 0.0203 0.0001 0.3772 0.3672 0.2649 0.4585 
β-catenin 0.3602 0.1151 0.4795 0.4448 0.0001 0.2325 0.5283 0.361 
MYC 0.1414 0.7378 0.4108 0.1474 0.107 0.0001 0.7553 0.4111 
Cyclin-D1 0.9747 0.5031 0.1926 0.3625 0.8308 0.6223 0.0001 0.0167 
















2.  FIGURES 
 
Figure 1: Morphologic spectrum of ES/PNET. A: Case 19: Classic ES with sheets of 
uniform, small, round, blue cells.  B: Case 25: PNET with Homer-Wright rosettes.  C: 
Case 21: Atypical ES with larger cells that often have a prominent nucleolus.  
Haematoxylin and eosin stain, 200x.  
 
Figure 2: Ewing sarcoma, haematoxylin and eosin stain (case 8), 200x. 

















Figure 3: Membranous CD99 expression (case 1), 200x 
 
 

















Figure 5: WNT5A cytoplasmic expression (case 7), 200x 
 
 

















Figure 7: GSK3β cytoplasmic expression (case 16), 200x 
 
 

















Figure 9: Nuclear β-catenin expression (case 22), 200x. 
 
 

















Figure 11: Cyclin D1 nuclear expression (case 20), 200x. 
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